Skip to main content
SpringerLink
Log in

Radiotherapy in the Management of Prostate Cancer

  • Chapter
  • First Online:
Controversies in Radiation Oncology

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 673 Accesses

Abstract

Prostate cancer remains one of the most common cancer diagnoses among men in North America. The majority are treated with surgery or radiotherapy; and the advent of technological precision has driven remarkable improvements in clinical outcomes. Here, we highlight existing controversies surrounding the use of radiotherapy in the management of prostate cancer, with specific focus on different clinical scenarios.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abdollah F, Cozzarini C, Sun M et al (2013) Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. Radiother Oncol 109(2):211–216

    Article  PubMed  Google Scholar 

  • Abdollah F, Karnes RJ, Suardi N et al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 32(35):3939–3947

    Article  PubMed  Google Scholar 

  • Aizer AA, Yu JB, McKeon AM et al (2009) Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 75(5):1344–1349

    Article  PubMed  Google Scholar 

  • Al-Mamgani A, van Putten WL, Heemsbergen WD et al (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72(4):980–988

    Article  PubMed  Google Scholar 

  • Al-Mamgani A, Heemsbergen WD, Peeters ST et al (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73(3):685–691

    Article  PubMed  Google Scholar 

  • Aluwini S, Pos F, Schimmel E et al (2015) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16(3):274–283

    Article  PubMed  Google Scholar 

  • Andriole GL, Crawford ED, Grubb RL 3rd et al (2009) PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Andriole GL, Crawford ED, Grubb RL 3rd et al.; PLCO Project Team (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125–132

    Google Scholar 

  • Antonarakis ES, Feng Z, Trock BJ et al (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 109(1):32–39

    Article  CAS  PubMed  Google Scholar 

  • Arcangeli G, Saracino B, Gomellini S et al (2010) A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 78(1):11–18

    Google Scholar 

  • Arcangeli S, Strigari L, Gomellini S et al (2012) Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 84(5):1172–1178

    Article  PubMed  Google Scholar 

  • Asbell SO, Krall JM, Pilepich MV et al (1988) Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15(6):1307–1316

    Article  CAS  PubMed  Google Scholar 

  • Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40(4):769–782

    Article  CAS  PubMed  Google Scholar 

  • Beckendorf V, Guerif S, Le Prisé E et al (2011) 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 80(4):1056–1063

    Article  PubMed  Google Scholar 

  • Bekelman JE, Hahn SM (2014) Reference pricing with evidence development: a way forward for proton therapy. J Clin Oncol 32(15):1540–1542

    Article  PubMed  PubMed Central  Google Scholar 

  • Bill-Axelson A, Holmberg L, Ruutu M et al.; SPCG-4 Investigators (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717

    Google Scholar 

  • Bill-Axelson A, Holmberg L, Garmo H et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370(10):932–942

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360(9327):103–106

    Article  CAS  PubMed  Google Scholar 

  • Bolla M, van Poppel H, Collette L et al.; European Organization for Research and Treatment of Cancer (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485):572–578

    Google Scholar 

  • Bolla M, de Reijke TM, Van Tienhoven G et al.; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527

    Google Scholar 

  • Bolla M, van Poppel H, Tombal B et al.; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018–2027

    Google Scholar 

  • Bolla M, Maingon P, Carrie C et al (2016) Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol 34(15):1748–1756

    Google Scholar 

  • Boorjian SA, Thompson RH, Siddiqui S et al (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178(3 Pt 1):864–870

    Article  PubMed  Google Scholar 

  • Boorjian SA, Karnes RJ, Viterbo R et al (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117(13):2883–2891

    Article  PubMed  Google Scholar 

  • Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101

    Article  CAS  PubMed  Google Scholar 

  • Briganti A, Chun FK, Karakiewicz PI et al (2008) Is node-positive prostate cancer always a systemic disease? Eur Urol 54(2):243–246

    Article  PubMed  Google Scholar 

  • Briganti A, Karnes JR, Da Pozzo LF et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55(2):261–270

    Article  PubMed  Google Scholar 

  • Briganti A, Larcher A, Abdollah F et al (2012a) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487

    Article  PubMed  Google Scholar 

  • Briganti A, Wiegel T, Joniau S et al (2012b) Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 62(3):472–487

    Article  PubMed  Google Scholar 

  • Carlsson SV, Tafe LJ, Chade DC et al (2013) Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol 189(4):1314–1318

    Article  PubMed  Google Scholar 

  • Cheng L, Zincke H, Blute ML et al (2001) Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91(1):66–73

    Article  CAS  PubMed  Google Scholar 

  • Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28(7):1117–1123

    Article  PubMed  PubMed Central  Google Scholar 

  • Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65(6):1058–1066

    Article  PubMed  Google Scholar 

  • D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974

    Article  PubMed  Google Scholar 

  • D'Amico AV, Manola J, Loffredo M et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292(7):821–827

    Article  CAS  PubMed  Google Scholar 

  • Dasu A, Toma-Dasu I (2012) Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncol 51(8):963–974

    Article  PubMed  Google Scholar 

  • Dearnaley D, Syndikus I, Sumo G et al (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13(1):43–54

    Article  PubMed  Google Scholar 

  • Dearnaley DP, Jovic G, Syndikus I et al (2014) Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 15(4):464–473

    Article  PubMed  Google Scholar 

  • Dearnaley DP, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1046–1060

    Google Scholar 

  • Den RB, Feng FY, Showalter TN et al (2014) Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int J Radiat Oncol Biol Phys 89(5):1038–1046

    Article  PubMed  PubMed Central  Google Scholar 

  • Den RB, Yousefi K, Trabulsi EJ et al (2015) Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol 33(8):944–951

    Article  PubMed  PubMed Central  Google Scholar 

  • Denham JW, Steigler A, Lamb DS et al.; Trans-Tasman Radiation Oncology Group (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6(11):841–850

    Google Scholar 

  • Eggener SE, Scardino PT, Walsh PC et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185(3):869–875

    Article  PubMed  PubMed Central  Google Scholar 

  • Engel J, Bastian PJ, Baur H et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57(5):754–761

    Article  PubMed  Google Scholar 

  • Evans JR, Zhao SG, Chang SL, et al. (2016) Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer. JAMA Oncol 2:1–10. doi: 10.1001/jamaoncol.2015.4955. [Epub ahead of print]

  • Freedland SJ, Rumble RB, Finelli A, et al.; American Society of Clinical Oncology (2014) Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 32(34):3892–3898

    Google Scholar 

  • Gakis G, Boorjian SA, Briganti A et al (2014) The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 66(2):191–199

    Article  PubMed  Google Scholar 

  • Galalae RM, Martinez A, Mate T et al (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58(4):1048–1055

    Article  PubMed  Google Scholar 

  • Gerber GS, Thisted RA, Chodak GW et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32(4):385–390

    Article  CAS  PubMed  Google Scholar 

  • Gray PJ, Paly JJ, Yeap BY et al (2013) Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119(9):1729–1735

    Article  PubMed  Google Scholar 

  • Grimm MO, Kamphausen S, Hugenschmidt H et al (2002) Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 41(6):628–634

    Article  PubMed  Google Scholar 

  • Grimm P, Billiet I, Bostwick D et al (2012) Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 109(Suppl 1):22–29

    Article  PubMed  Google Scholar 

  • Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heemsbergen WD, Al-Mamgani A, Slot A et al (2014) Long-term results of the Dutch randomized prostate cancer: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 110(1):104–109

    Article  PubMed  Google Scholar 

  • Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37

    Article  PubMed  Google Scholar 

  • Heijnsdijk EA, Wever EM, Auvinen A et al (2012) Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 367(7):595–605

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Herbert C, Liu M, Tyldesley S et al (2012) Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%. Int J Radiat Oncol Biol Phys 83(1):22–27

    Article  PubMed  Google Scholar 

  • Hoffman KE, Voong KR, Pugh TJ et al (2014) Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. Int J Radiat Oncol Biol Phys 88(5):1074–1084

    Google Scholar 

  • Hong MK, Macintyre G, Wedge DC et al (2015) Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605

    Article  CAS  PubMed  Google Scholar 

  • Hoppe BS, Michalski JM, Mendenhall NP et al (2014) Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120(7):1076–1082

    Article  PubMed  Google Scholar 

  • Horwitz EM, Bae K, Hanks GE et al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26(15):2497–2504

    Article  CAS  PubMed  Google Scholar 

  • Hoskin PJ, Rojas AM, Bownes PJ et al (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103(2):217–222

    Article  PubMed  Google Scholar 

  • Iyengar P, Levy LB, Choi S et al (2011) Toxicity associated with postoperative radiation therapy for prostate cancer. Am J Clin Oncol 34(6):611–618

    Article  PubMed  Google Scholar 

  • Jacob R, Hanlon AL, Horwitz EM et al (2005) Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61(3):695–701

    Article  PubMed  Google Scholar 

  • James ND, Spears MR, Clarke NW et al.; STAMPEDE Investigators (2015a) Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol:1–10. doi: 10.1001/jamaoncol.2015.4350. [Epub ahead of print]

  • James ND, Spears MR, Clarke NW et al (2015b) Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67(6):1028–1038

    Article  PubMed  Google Scholar 

  • Jones CU, Hunt D, McGowan DG et al (2011) Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 365(2):107–118

    Article  CAS  PubMed  Google Scholar 

  • Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68(1):121–125

    Article  PubMed  Google Scholar 

  • Kattan MW, Zelefsky MJ, Kupelian PA et al (2003) Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 21(24):4568–4571

    Article  PubMed  Google Scholar 

  • Kim DW, Cho LC, Straka C et al (2014) Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89(3):509–517

    Article  PubMed  Google Scholar 

  • Koukourakis G, Kelekis N, Armonis V et al (2009) Brachytherapy for prostate cancer: a systematic review. Adv Urol 2009:327945. doi:10.1155/2009/327945

    Article  PubMed Central  Google Scholar 

  • Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74

    Article  PubMed  Google Scholar 

  • Kuban DA, Levy LB, Cheung MR et al (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79(5):1310–1317

    Article  PubMed  Google Scholar 

  • Kupelian PA, Elshaikh M, Reddy CA et al (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20(16):3376–3385

    Article  PubMed  Google Scholar 

  • Lalonde E, Ishkanian AS, Sykes J et al (2014) Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 15(13):1521–1532

    Article  PubMed  Google Scholar 

  • Lane JA, Hamdy FC, Martin RM et al (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 46(17):3095–3101

    Article  CAS  PubMed  Google Scholar 

  • Lane JA, Donovan JL, Davis M et al.; ProtecT study group (2014) Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 15(10):1109–1118.

    Google Scholar 

  • Lawrence TS, Feng M (2013) Protons for prostate cancer: the dream versus the reality. J Natl Cancer Inst 105(1):7–8

    Article  PubMed  Google Scholar 

  • Lawton CA, Winter K, Grignon D et al (2005) Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31. J Clin Oncol 23(4):800–807

    Article  PubMed  Google Scholar 

  • Lawton CA, DeSilvio M, Roach M 3rd et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646–655

    Article  PubMed  PubMed Central  Google Scholar 

  • Lawton CA, Michalski J, El-Naqa I et al (2009) RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74(2):383–387

    Article  PubMed  Google Scholar 

  • Lee WR, Dignam JJ, Amin MB et al (2016) Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 34(20):2325–2332

    Google Scholar 

  • Lin CC, Gray PJ, Jemal A, Efstathiou JA (2015) Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst 107(7)

    Google Scholar 

  • Lukka H, Hayter C, Julian JA et al (2005) Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 23:6132–6138

    Article  PubMed  Google Scholar 

  • Mantini G, Tagliaferri L, Mattiucci GC et al (2011) Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys 81(5):e721–e726

    Article  PubMed  Google Scholar 

  • Martinez AA, Gustafson G, Gonzalez J et al (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53(2):316–327

    Article  PubMed  Google Scholar 

  • Martinez AA, Gonzalez J, Ye H et al (2011) Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 79(2):363–370

    Article  PubMed  Google Scholar 

  • Mason MD, Parulekar WR, Sydes MR et al (2015) Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol 33(19):2143–2150

    Article  PubMed  PubMed Central  Google Scholar 

  • Mendenhall NP, Hoppe BS, Nichols RC et al (2014) Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 88(3):596–602

    Article  PubMed  Google Scholar 

  • Messing EM, Manola J, Yao J et al.; Eastern Cooperative Oncology Group study EST 3886 (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7(6):472–479.

    Google Scholar 

  • Michalski JM, Yan Y, Watkins-Bruner D et al (2013) Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys 87(5):932–938

    Article  PubMed  Google Scholar 

  • Michalski JM, Moughan J, Purdy JA et al (2014) Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126). Int J Radiat Oncol Biol Phys 90(5):1263

    Google Scholar 

  • Michalski JM, Moughan J, Purdy J et al (2015) A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. J Clin Oncol 33(suppl 7; abstr 4)

    Google Scholar 

  • Milecki P, Baczyk M, Skowronek J et al (2009) Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. J Biomed Biotechnol 2009:625394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17–e24

    Article  PubMed  Google Scholar 

  • Mitchell JM (2013) Urologists’ use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med 369(17):1629–1637

    Article  CAS  PubMed  Google Scholar 

  • Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV (2014) Prostate cancer, version 2.2014. J Natl Compr Canc Netw 12(5):686–718

    Article  CAS  PubMed  Google Scholar 

  • Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C et al (2011) Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer? Radiother Oncol 100(3):463–467

    Article  PubMed  Google Scholar 

  • Nabid A, Carrier N, Martin AG et al. (2013) Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized trial. J Clin Oncol 31(suppl; abstr LBA4510)

    Google Scholar 

  • Nabid A, Carrier N, Vigneault E, Souhami L, Lemaire C, Brassard MA (2015) Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: a phase III trial. J Clin Oncol 33(suppl 7; abstr 5)

    Google Scholar 

  • Nguyen PL, Chen MH, Hoffman KE et al (2009) Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 74(1):104–109

    Article  PubMed  Google Scholar 

  • Ost P, Jereczek-Fossa BA, As NV et al (2016) Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a Multi-institutional Analysis. Eur Urol 69(1):9–12

    Article  PubMed  Google Scholar 

  • Pan CC, Kim KY, Taylor JM et al (2002) Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53(5):1139–1145

    Article  CAS  PubMed  Google Scholar 

  • Parikh R, Sher DJ (2012) Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis. Cancer 118(1):258–267

    Article  PubMed  Google Scholar 

  • Parker C, Sydes MR, Catton C, et al.; (RADICALS Trial Management Group) (2007) Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 99(6):1376–1379

    Google Scholar 

  • Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD (2001) Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58(6):843–848

    Article  CAS  PubMed  Google Scholar 

  • Pearse M, Fraser-Browne C, Davis ID et al (2014) A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial. BJU Int 113(Suppl 2):7–12

    Article  PubMed  Google Scholar 

  • Peinemann F, Grouven U, Hemkens LG et al (2011) Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev (7):CD008871

    Google Scholar 

  • Pfister D, Bolla M, Briganti A et al (2014) Early salvage radiotherapy following radical prostatectomy. Eur Urol 65(6):1034–1043

    Article  PubMed  Google Scholar 

  • Pollack A, Zagars GK, Smith LG et al (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18(23):3904–3911

    Article  CAS  PubMed  Google Scholar 

  • Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53(5):1097–1105

    Article  PubMed  Google Scholar 

  • Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA et al (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 31(31):3860–3868

    Article  PubMed  PubMed Central  Google Scholar 

  • Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25(34):5366–5373

    Article  PubMed  Google Scholar 

  • Porter CR, Kodama K, Gibbons RP et al (2006) 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176(2):569–574

    Article  PubMed  Google Scholar 

  • Potosky AL, Miller BA, Albertsen PC et al (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273(7):548–552

    Article  CAS  PubMed  Google Scholar 

  • Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597

    Article  CAS  PubMed  Google Scholar 

  • Resnick MJ, Koyama T, Fan KH et al (2013) Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 368(5):436–445

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Roach M 3rd, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28(1):33–37

    Article  PubMed  Google Scholar 

  • Roach M 3rd, DeSilvio M, Lawton C et al.; Radiation Therapy Oncology Group 9413 (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21(10):1904–1911.

    Google Scholar 

  • Roobol MJ, Bokhorst LP (2014) The ProtecT trial: what can we expect? Lancet Oncol 15(10):1046–1047

    Article  PubMed  Google Scholar 

  • Rusthoven CG, Carlson JA, Waxweiler TV et al (2014) The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys 88(5):1064–1073

    Article  PubMed  Google Scholar 

  • Schmidt-Hansen M, Hoskin P, Kirkbride P et al (2014) Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. Clin Oncol (R CollRadiol) 26(10):e21–e46

    Article  CAS  Google Scholar 

  • Schröder FH, Hugosson J, Roobol MJ et al.; ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328.

    Google Scholar 

  • Schröder FH, Hugosson J, Roobol MJ et al (2012) ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990

    Article  PubMed  PubMed Central  Google Scholar 

  • Schröder FH, Hugosson J, Roobol MJ et al.; for the ERSPC Investigators (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959):2027–2035.

    Google Scholar 

  • Schumacher MC, Burkhard FC, Thalmann GN et al (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54(2):344–352

    Article  PubMed  Google Scholar 

  • Seaward SA, Weinberg V, Lewis P et al (1998a) Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42(5):1055–1062

    Article  CAS  PubMed  Google Scholar 

  • Seaward SA, Weinberg V, Lewis P et al (1998b) Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am 4(6):370–377

    CAS  PubMed  Google Scholar 

  • Sheets NC, Goldin GH, Meyer AM et al (2012) Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA 307(15):1611–1620

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sineshaw HM, Gray PJ, Efstathiou JA et al (2015) Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. Eur Urol 68(5):768–774

    Google Scholar 

  • Sooriakumaran P, Nyberg T, Akre O et al (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348:g1502. doi:10.1136/bmj.g1502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041

    Article  PubMed  Google Scholar 

  • Steuber T, Budäus L, Walz J et al (2011) Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 107(11):1755–1761

    Article  PubMed  Google Scholar 

  • Swanson GP, Thompson IM, Basler J (2006) Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 107(3):439–450

    Article  PubMed  Google Scholar 

  • Taylor A, Rockall AG, Powell ME (2007) An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clin Oncol (R Coll Radiol) 19(7):542–550

    Article  CAS  Google Scholar 

  • Thompson IM, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296(19):2329–2335

    Article  CAS  PubMed  Google Scholar 

  • Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956–962

    Article  PubMed  PubMed Central  Google Scholar 

  • Touijer KA, Mazzola CR, Sjoberg DD et al (2014) Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65(1):20–25

    Article  PubMed  Google Scholar 

  • Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299(23):2760–2769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tward JD, Kokeny KE, Shrieve DC (2013) Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol 3(3):234–240

    Article  PubMed  Google Scholar 

  • Valicenti RK, Thompson I Jr, Albertsen P et al.; American Society for Radiation Oncology/American Urological Association (2013) Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys 86(5):822–828.

    Google Scholar 

  • van den Bergh RC, Ahmed HU, Bangma CH et al (2014) Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. Eur Urol 65(6):1023–1031

    Article  PubMed  Google Scholar 

  • Van der Kwast T, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178–4186

    Article  PubMed  Google Scholar 

  • Viers BR, Sukov WR, Gettman MT et al (2014) Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Eur Urol 66(6):1116–1124

    Article  PubMed  Google Scholar 

  • Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85(1):89–94

    Article  PubMed  Google Scholar 

  • von Bodman C, Godoy G, Chade DC et al (2010) Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol 184(1):143–148

    Article  Google Scholar 

  • Wallis CJD, Saskin R, Choo R et al (2015) Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70(1):21–30

    Article  PubMed  Google Scholar 

  • Warde P, Mason M, Ding K et al.; NCIC CTG PR.3/MRC UK PR07 investigators (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378(9809):2104–2111

    Google Scholar 

  • Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101(19):1325–1329

    Article  PubMed  PubMed Central  Google Scholar 

  • Widmark A, Klepp O, Solberg A et al.; Scandinavian Prostate Cancer Group Study 7; Swedish Association for Urological Oncology 3 (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308

    Google Scholar 

  • Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27(18):2924–2930

    Article  PubMed  Google Scholar 

  • Wiegel T, Bartkowiak D, Bottke D et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 66(2):243–250

    Article  PubMed  Google Scholar 

  • Wiegel T, Bartkowiak D, Bottke D et al (2015) Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year Data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys 91(2):288–294

    Article  PubMed  Google Scholar 

  • Wilt TJ, Brawer MK, Jones KM et al.; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203–213.

    Google Scholar 

  • Yeoh EE, Holloway RH, Fraser RJ et al (2006) Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66:1072–1083

    Google Scholar 

  • Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J (2011) Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81(5):1271–1278

    Article  PubMed  Google Scholar 

  • Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP et al (2014) Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol 32(12):1195–1201

    Article  PubMed  PubMed Central  Google Scholar 

  • Zagars GK, Pollack A, von Eschenbach AC (2001) Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology 58(2):233–239

    Article  CAS  PubMed  Google Scholar 

  • Zapatero A, Guerrero A, Maldonado J et al (2015) High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 16(3):320–327

    Article  CAS  PubMed  Google Scholar 

  • Zelefsky MJ, Leibel SA, Gaudin PB et al (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41(3):491–500

    Article  CAS  PubMed  Google Scholar 

  • Zelefsky MJ, Eastham JA, Cronin AM et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28(9):1508–1513

    Article  PubMed  PubMed Central  Google Scholar 

  • Zelefsky MJ, Pei X, Chou JF et al (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60(6):1133–1139

    Article  PubMed  Google Scholar 

  • Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28(7):1106–1111

    Article  PubMed  PubMed Central  Google Scholar 

  • Zumsteg ZS, Spratt DE, Pei I et al (2013) A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol 64(6):895–902

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Radiation Oncology, National Cancer Centre, Singapore, Singapore

    Melvin Lee Kiang Chua MBBS, FRCR, PhD

  2. Duke-NUS Graduate Medical School, Singapore, Singapore

    Melvin Lee Kiang Chua MBBS, FRCR, PhD

  3. Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada

    Melvin Lee Kiang Chua MBBS, FRCR, PhD

  4. Department of Oncology and Nuclear Medicine, University Hospital Sisters of Charity, University of Zagreb Medical School, Zagreb, Croatia

    Jure Murgic MD

  5. Department of Radiation Oncology, Houston Methodist Hospital, Cancer Center and Research Institute, Weil Cornell Medical College, Houston, TX, USA

    E. Brian Butler MD & Bin S. Teh MD

Authors
  1. Melvin Lee Kiang Chua MBBS, FRCR, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jure Murgic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Brian Butler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin S. Teh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bin S. Teh MD .

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA

    Simon S. Lo

  2. Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA

    Bin S. Teh

  3. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

    Guo-Liang Jiang

  4. Department of Radiation Oncology, University of Washington, Seattle, WA, USA

    Nina A. Mayr

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Chua, M.L.K., Murgic, J., Butler, E.B., Teh, B.S. (2017). Radiotherapy in the Management of Prostate Cancer. In: Lo, S., Teh, B., Jiang, GL., Mayr, N. (eds) Controversies in Radiation Oncology. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2017_11

Download citation

  • DOI: https://doi.org/10.1007/174_2017_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-51194-8

  • Online ISBN: 978-3-319-51196-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation